Vivimed Labs (NSE:VIVIMEDLAB) EPS without NRI: ₹-4.15 (TTM As of Dec. 2025)


NSE:VIVIMEDLAB Vivimed Labs Ltd NSE:VIVIMEDLAB
47 GF Score
Price ₹5.79
GF Value ₹2.55
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Vivimed Labs EPS without NRI?

Vivimed Labs NSE:VIVIMEDLAB +1.05% 47 EPS without NRI is ₹-4.15 as of Dec. 2025. GuruFocus rates NSE:VIVIMEDLAB with a GF Score™ of 47/100 and a GF Value™ of ₹2.55 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 785 Drug Manufacturers companies, Vivimed Labs ranks better than 67.26% on this metric.

Vivimed Labs's earnings per share without non-recurring items for the three months ended in Dec. 2025 was ₹-1.94. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was ₹-4.15.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 21.40% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 21.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Vivimed Labs's EPS without NRI or its related term are showing as below:

NSE:VIVIMEDLAB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.9   Med: 21.4   Max: 68.8
Current: 21.4

During the past 13 years, Vivimed Labs's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 68.80% per year. The lowest was -48.90% per year. And the median was 21.40% per year.

NSE:VIVIMEDLAB's 3-Year EPS without NRI Growth Rate is ranked better than
67.26% of 785 companies
in the Drug Manufacturers industry
Industry Median: 9.7 vs NSE:VIVIMEDLAB: 21.40

Vivimed Labs's EPS (Diluted) for the three months ended in Dec. 2025 was ₹-2.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was ₹-4.21.

Vivimed Labs's EPS (Basic) for the three months ended in Dec. 2025 was ₹-2.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was ₹-4.21.


Vivimed Labs  (NSE:VIVIMEDLAB) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Vivimed Labs EPS without NRI Related Terms


Vivimed Labs EPS without NRI Historical Data

* Premium members only.

The historical data trend for Vivimed Labs's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivimed Labs EPS without NRI Chart

Vivimed Labs Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.11 -7.92 -29.19 -2.35 -3.85

Vivimed Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.72 -0.67 -0.66 -0.88 -1.94

NSE:VIVIMEDLAB vs ZTS, UTHR: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vivimed Labs's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivimed Labs PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vivimed Labs's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Vivimed Labs's PE Ratio without NRI falls into.


NSE:VIVIMEDLAB
47GF Score
Vivimed Labs Ltd NSE:VIVIMEDLAB
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivimed Labs EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-4.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of ₹-4.15 mean?
Vivimed Labs (NSE:VIVIMEDLAB) has a EPS without NRI of ₹-4.15 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Vivimed Labs and its competitors. According to the industry distribution chart, Vivimed Labs ranks #257 out of 785 companies in the Drug Manufacturers industry, placing it in the top 32.7%.
Is Vivimed Labs' EPS without NRI too high?
Vivimed Labs' current EPS without NRI is ₹-4.15. Based on the distribution chart, Vivimed Labs ranks #257 out of 785 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vivimed Labs has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vivimed Labs' EPS without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vivimed Labs ranks #257 out of 785 companies for EPS without NRI. This puts Vivimed Labs in the upper half of its industry. The industry median EPS without NRI is 9.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.70, based on 785 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Vivimed Labs and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivimed Labs's current EPS without NRI is ₹-4.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivimed Labs stock overvalued right now?
Based on GuruFocus' analysis, Vivimed Labs (NSE:VIVIMEDLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.55, compared to a current price of ₹5.79 — trading 127.1% above its estimated fair value. The current EPS without NRI is ₹-4.15. Vivimed Labs' overall GF Score™ is 47/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Vivimed Labs (NSE:VIVIMEDLAB), the current EPS without NRI is ₹-4.15 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vivimed Labs (NSE:VIVIMEDLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Vivimed Labs stock appears to be overvalued. The current stock price of ₹5.79 is trading 127.1% above its estimated GF Value™ of ₹2.55. GuruFocus considers Vivimed Labs to be Significantly Overvalued.

Key valuation signals for NSE:VIVIMEDLAB:

  • EPS without NRI: ₹-4.15
  • GF Value™: ₹2.55 vs. price of ₹5.79 (127.1% above fair value)
  • GF Score™: 47/100 with 7 warning signs

No single metric tells the full story. See the NSE:VIVIMEDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vivimed Labs Business Description

Other Exchanges 532660:India
Address Green Lands, Beside The Plaza Hotel, D.No. 6-3-866/1/G1, 3rd & 4th Floor, GMR Towers, Begumpet, Hyderabad, TG, IND, 500016
Vivimed Labs Ltd is an India-based company that is engaged in the Business of Active pharmaceutical ingredients, Intermediates, Nutraceutical ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals, and Retail Branded Formulation manufacturing. The company has three reportable segments: the Speciality Chemicals Business, the Pharma Business, and others. The majority of revenue is earned through the Pharma business.
47GF Score

Get the complete analysis for NSE:VIVIMEDLAB

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹5.79
Price
₹2.55
GF Value